Table 1.

Research protocols for anti-inflammatory and antioxidant therapy for chronic chagasic myocarditis

Author	Study design	Aim	Population	Inclusion criteria	Exclusion criteria	Intervention
Silva et al. (2013)	Parallel, double-blind, placebo-controlled clinical trial with balanced randomisation	To study the effects of omega-3 fatty acid supplementation on the inflammatory response and lipid profile in patients with Chagas cardiomyopathy.	20 patients in each group (n = 40)	Patients with chronic Chagas cardiomyopathy aged 18 years or older	In progress of: diarrheal disease, inflammatory bowel disease, diabetes or other endocrine disease; In use of a fibrate, niacin, or statins, anti-inflammatory drugs; Pregnant and lactating women, the use of vitamins, minerals and omega-3 supplementation during the previous 30 days; Hospitalization during the study and other cardiomyopathies.	Omega-3 polyunsaturated fatty acids at the dose of 3 g day−1 or placebo (corn oil) for 8 weeks (56 days).
Alvarenga Americano do Brasil et al. (2014)	Unicentric, double-blind, placebo-controlled study, randomised clinical superiority trial.	To estimate the effect of selenium treatment on the prevention of progression of heart disease in patients with Chagas cardiomyopathy	65 patients in each group (n = 130)	Diagnosis of Chagas disease confirmed by serology; Segmental, mild or moderate left ventricular systolic dysfunction; Age between 18 and 65 years.	Pregnancy, diabetes mellitus; In tobacco use, alcohol abuse; Evidence of non-Chagas' heart disease; Depression; Dysphagia with evidence of food residues in the esophagus, dysphagia with weight loss greater than 15% of the usual weight in the last 4 months; Conditions that may result in low protocol adherence.	100 μg sodium selenite capsules or placebo capsules orally once daily for 365 days.
Macedo et al. (2012)	Single-centre, prospective, single-cohort study with therapeutic intervention followed by quantitative reassessment	To analyse the verapamil and acetylsalicylic acid of the ventricular area with ischemic perfusion changes in chagasic cardiopathy patients with angiographically normal coronary arteries	125 patients	Chagasic patients who have undergone cardiac catheterisation Indication of the examination due to precordial pain, with normal coronary angiographically or without lesions > 30%; with preserved or only mildly compromised overall systolic left ventricular function (left ventricular ejection fraction > 40%); With regional contractile dysfunction suggestive of CCC; Two positive serological tests for Chagas disease with different methods.	History of diabetes mellitus, severe systemic arterial hypertension (mild or even moderate controlled degrees, are acceptable); Heart rate <60 bpm or systolic blood pressure <90 mmHg, and use or clinical need for negative chronotropic medication (digitalis, adrenergic beta blocker or amiodarone).	Acetylsalicylic acid (100 mg daily dose) associated with verapamil (daily dose of 160 mg in two 80 mg doses).